Nondamaging retinal laser therapy in recurrent diabetic macular edema after antiVEGF injections

Background/aim: Subthreshold yellow nondamaging retinal laser therapy (NRT) could provide a greater safety profile when compared to conventional laser methods. NRT may also improve diabetic macular edema (DME). This study aims to assess whether the severity of DME affects the efficacy of subthreshold yellow NRT. Materials and methods: The study included 70 eyes that had previously been treated with ranibizumab for DME and then developed recurrent macular edema, which was treated with NRT once. The central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were evaluated retrospectively 2 months following the NRT. The eyes in the study were divided into 4 different groups according to the baseline CFT values. The initial CFT was 250–300 μm in Group 1 (n = 26), 301–400 μm in Group 2 (n = 24), and >401 μm in Group 3 (n = 20). Group 4 (n = 20) included control subjects with 250–300 µm CFT, diagnosed with DME, and not previously treated. The alterations in the BCVA and CFT were measured. Results: In the study, it was determined that 45 right eyes and 45 left eyes were involved. Statistically significant decrements (42.84 m reduction) in CFT were detected only in the Group 1 (p = 0.01). There was no significant improvement in CFT within Group 2, 3 and 4 (p = 0.29, p = 0.73, p = 0.22, respectively). Solely Group 1 had statistically significant improvement (from 0.54 to 0.39 LogMAR) in BCVA (p = 0.01), while groups 2, 3 and 4 had no improvement at all (p = 0.74, p = 0.96, p = 0.66 respectively). Conclusions: Based on the results, NRT provided an improvement in BCVA and CFT in eyes with CFT less than 300 µm at the shortterm follow-up. However, CFT and BCVA outcomes after NRT were inferior to those achieved after previous ranibizumab treatment. No positive effect of NRT was not observed in patients with moderate and severe macular edema in DME treatment.Key words: Central foveal thickness, diabetic macular edema, subthreshold laser, nondamaging retinal laser

PDF

___

1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995; 102: 7-16. doi: 10.1016/s0161-6420(95)31052-4
2. Moisseiev E, Loewenstein A. Diabetic macular edema: emerging strategies and treatment algorithms. Developments in Ophthalmology 2017; 60: 165-174. doi: 10.1159/000459706
3. Pollack JS, Kim JE, Pulido JS, Burke JM. Tissue effects of subclinical diode laser treatment of the retina. Archives of Ophthalmology 1998; 116: 1633-1639. doi: 10.1001/archopht.116.12.1633
4. Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H et al. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Investigative Ophthalmology & Visual Science 2011; 52: 1780-1787. doi: 10.1167/iovs.10-5917
5. Lavinsky D, Sramek C, Wang J, Huie P, Dalal R et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014; 34: 87-97. doi: 10.1097/IAE.0b013e3182993edc
6. Palanker D. Evolution of concepts and technologies in ophthalmic laser therapy. Annual Review of Vision Science 2016; 2: 295-319. doi: 10.1146/annurev-vision-111815- 114358
7. Sramek CK, Leung LS, Paulus YM, Palanker DV. Therapeutic window of retinal photocoagulation with green (532-nm) and yellow (577-nm) lasers. Ophthalmic Surgery Lasers and Imaging 2012; 43: 341-347. doi: 10.3928/15428877- 20120426-05
8. Kwon YH, Lee DK, Kwon OW. The short-term efficacy of subthreshold Micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean Journal of Ophthalmology 2014; 28: 379-385. doi: 10.3341/kjo.2014.28.5.379
9. Lavinsky D, Wang J, Huie P, Dalal R, Lee SJ et al. Nondamaging retinal laser therapy: rationale and applications to the Macula. Investigative Ophthalmology & Visual Science. 2016; 57: 2488- 2500. doi: 10.1167/iovs.15-18981
10. Sramek C, Paulus Y, Nomoto H, Huie P, Brown J. Dynamics of retinal photocoagulation and rupture. Journal of Biomedical Optics 2009; 14: 034007. doi: 10.1117/1.3130282
11. Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the Evidence? Retina 2017; 37: 1021-1033. doi: 10.1097/IAE.0000000000001386
12. Mansouri A, Sampat KM, Malik KJ, Steiner JN, Glaser BM; Medscape. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pretreatment central foveal thickness. Eye (London) 2014; 28: 1418-1424. doi: 10.1038/eye.2014.264
13. Ulbig MW, McHugh DA, Hamilton AM. Diode laser photocoagulation for diabetic macular oedema. British Journal of Ophthalmology 1995; 79: 318-321. doi: 10.1136/bjo.79.4.318
14. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. British Journal of Ophthalmology 2005; 89: 74-80. doi: 10.1136/bjo.2004.051540
15. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al. Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica 2017; 237: 185-222. doi: 10.1159/000458539
16. Moore SM, Chao DL. Application of subthreshold laser therapy in retinal diseases: a review. Expert Review of Ophthalmology 2018; 13: 311-320. doi: 10.1080/17469899.2018